SBC

In the past six months, SBC Medical Group Holdings, Inc.'s stock has been impacted by several events. In August 2026, the company reported its second-quarter 2026 earnings, with revenues exceeding analysts' expectations at US$49.2 million (up 13% from Q2 2025), but earnings per share (EPS) lagged estimates at US$0.10 (an increase from US$0.024 in Q2 2025). Net income saw a substantial increase of 335% to US$10.7 million. In July 2026, SBC Medical Group Incorporated received a written notice from Nasdaq's Listing Qualifications Department due to non-compliance with independent director and audit committee requirements, and was provided a cure period. The company actively participated in investor relations, attending several investor conferences in September 2026, including the CLSA 33rd Investors' Forum, the ArcStone-Kingswood Growth Summit, and the H.C. Wainwright 28th Annual Global Investment Conference. Earlier, in May 2026, the company announced its first-quarter 2026 financial results, reporting total revenues of $43 million (a 9% year-over-year decrease) and net income of $11 million (a 47% year-over-year decrease). As of September 21, 2026, the stock has shown volatility, rising 35.87% over the last month and 31.58% over the last six months.